New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

P140 is ImmuPharma’s technology platform for its portfolio in autoimmune diseases. This comprises the lead indication commencing a Phase 3 clinical study in systemic lupus erythematosus (“SLE”) and the second indication, in preparation for a Phase 2/3 adaptive clinical study in chronic idiopathic demyelinating polyneuropathy (“CIDP”).

New insights into the P140 technology lends itself to expanding the current patent portfolio. This new patent initiative will strengthen the commercial value of P140 and add to the positive engagement we are already experiencing in discussions with a broad range of potential commercial partners on SLE and CIDP.

New patents will not only significantly enhance the patent protection for P140 in SLE and CIDP but will also support patient studies in other auto-immune/inflammatory diseases and release further value from the P140 technology platform.

Commenting on the announcement, Tim McCarthy, CEO of ImmuPharma, said:

“This is an important new initiative which will greatly improve the intellectual property protection for our P140 technology platform and extend its patent life significantly. This in turn creates greater shareholder value and it is particularly pertinent as we progress discussions with a broad range of potential commercial partners on both the SLE and CIDP programs.”

To download this announcement click here

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.